Regular Cannabis Users ‘Have Better Blood Sugar Control’

“People who regularly use cannabis have better blood sugar control than those who do not, providing implications for use of the drug in diabetic control.”

Cannabis users have lower blood sugar levels than non-users (Reuters)

“Research published in the American Journal of Medicine found current marijuana users are less likely to be insulin resistant and have significantly lower fasting insulin levels, even after patients with diabetes were excluded from the study. 

The ream found cannabis users’ fasting insulin levels were 16% lower than non-users…

Cannabis in becoming increasingly used for medical purposes, with the active ingredient tetrahydrocannabinol (THC) approved in the US as a treatment for the side effect of chemotherapy. It is legal for recreational use in two states and 19 for medical use.

The researchers looked at data obtained through the National Health and Nutrition Survey between 2005 and 2010.

They looked at questionnaires from 4,657 people, of which 579 were regular cannabis users, 1,975 had used marijuana but not regularly and 2,103 had never used the drug.

Insulin and glucose were measured through blood samples after a nine hour fast and insulin resistance was calculated.

The team found that people who had used cannabis in the last month had lower levels of fasting insulin and insulin resistance and higher levels of high-density lipoprotein cholesterol (HDL-C), which is associated with better cardiovascular health…”

Read more: http://www.ibtimes.co.uk/articles/467817/20130515/cannabis-marijuana-lower-blood-sugar-levels-diabetes.htm

Marijuana for Diabetic Control

“For centuries, cannabis sativa, more commonly known as marijuana, has been used as a folk remedy to relieve pain, improve mood, and increase appetite…

Much of what we know about cannabis comes from folktales and limited clinical observation. It was in this context that I was pleased to receive the submission published in this edition of The American Journal of Medicine, entitled “The Impact of Marijuana Use on Glucose, Insulin, and Insulin Resistance Among US Adults.” This epidemiologic, observational study demonstrated that among diabetic patients who admitted to using marijuana, insulin resistance was decreased and diabetic control was improved. Penner et al analyzed data obtained during the National Health and Nutrition Survey between 2005 and 2010. They studied data from 4657 patients, of whom 579 were current users of cannabis, 1975 used cannabis in the past but were not current users, and 2103 had never inhaled or ingested marijuana. These patients had fasting insulin and glucose levels measured along with a test for insulin resistance.

 Remarkably, fasting insulin levels were reduced in current cannabis users but not in former or never users. Two additional observations were that waist circumference was smaller and high-density lipoprotein cholesterol blood levels were higher in current cannabis users.

These are indeed remarkable observations that are supported, as the authors note, by basic science experiments that came to similar conclusions…”

http://www.amjmed.com/article/S0002-9343(13)00313-6/fulltext

Novel study reports marijuana users have better blood sugar control

“Regular marijuana use is associated with favorable indices related to diabetic control, say investigators. They found that current marijuana users had significantly lower fasting insulin and were less likely to be insulin resistant, even after excluding patients with a diagnosis of diabetes mellitus. Their findings are reported in the current issue of The American Journal of Medicine

Editor-in-Chief Joseph S. Alpert, MD, Professor of Medicine at the University of Arizona College of Medicine, Tucson, comments, “These are indeed remarkable observations that are supported, as the authors note, by basic science experiments that came to similar conclusions.

“We desperately need a great deal more basic and clinical research into the short- and long-term effects of marijuana in a variety of clinical settings such as cancer, diabetes, and frailty of the elderly,” continues Alpert.” I would like to call on the NIH and the DEA to collaborate in developing policies to implement solid scientific investigations that would lead to information assisting physicians in the proper use and prescription of THC in its synthetic or herbal form.””

Read more: http://medicalxpress.com/news/2013-05-marijuana-users-blood-sugar.html 

Marijuana Users Have Better Blood Sugar Control – ScienceDaily

“May 15, 2013 — Regular marijuana use is associated with favorable indices related to diabetic control, say investigators. They found that current marijuana users had significantly lower fasting insulin and were less likely to be insulin resistant, even after excluding patients with a diagnosis of diabetes mellitus. Their findings are reported in the current issue of The American Journal of Medicine.

Marijuana (Cannabis sativa) has been used for centuries to relieve pain, improve mood, and increase appetite. Outlawed in the United States in 1937, its social use continues to increase and public opinion is swinging in favor of the medicinal use of marijuana. There are an estimated 17.4 million current users of marijuana in the United States. Approximately 4.6 million of these users smoke marijuana daily or almost daily. A synthetic form of its active ingredient, tetrahydrocannabinol, commonly known as THC, has already been approved to treat side-effects of chemotherapy, AIDS-induced anorexia, nausea, and other medical conditions. With the recent legalization of recreational marijuana in two states and the legalization of medical marijuana in 19 states and the District of Columbia, physicians will increasingly encounter marijuana use among their patient populations.

A multicenter research team analyzed data obtained during the National Health and Nutrition Survey (NHANES) between 2005 and 2010. They studied data from 4,657 patients who completed a drug use questionnaire. Of these, 579 were current marijuana users, 1,975 had used marijuana in the past but were not current users, and 2,103 had never inhaled or ingested marijuana. Fasting insulin and glucose were measured via blood samples following a nine hour fast, and homeostasis model assessment of insulin resistance (HOMA-IR) was calculated to evaluate insulin resistance.

Participants who reported using marijuana in the past month had lower levels of fasting insulin and HOMA-IR and higher levels of high-density lipoprotein cholesterol (HDL-C). These associations were weaker among those who reported using marijuana at least once, but not in the past thirty days, suggesting that the impact of marijuana use on insulin and insulin resistance exists during periods of recent use. Current users had 16% lower fasting insulin levels than participants who reported never having used marijuana in their lifetimes.

Large waist circumference is linked to diabetes risk. In the current study there were also significant associations between marijuana use and smaller waist circumferences.

“Previous epidemiologic studies have found lower prevalence rates of obesity and diabetes mellitus in marijuana users compared to people who have never used marijuana, suggesting a relationship between cannabinoids and peripheral metabolic processes, but ours is the first study to investigate the relationship between marijuana use and fasting insulin, glucose, and insulin resistance,” says lead investigator Murray A. Mittleman, MD, DrPH, of the Cardiovascular Epidemiology Research Unit at the Beth Israel Deaconess Medical Center, Boston.

“It is possible that the inverse association in fasting insulin levels and insulin resistance seen among current marijuana users could be in part due to changes in usage patterns among those with a diagnosis of diabetes (i.e., those with diabetes may have been told to cease smoking). However, after we excluded those subjects with a diagnosis of diabetes mellitus, the associations between marijuana use and insulin levels, HOMA-IR, waist circumference, and HDL-C were similar and remained statistically significant,” states Elizabeth Penner, MD, MPH, an author of the study.

Although people who smoke marijuana have higher average caloric intake levels than non-users, marijuana use has been associated with lower body-mass index (BMI) in two previous surveys. “The mechanisms underlying this paradox have not been determined and the impact of regular marijuana use on insulin resistance and cardiometabolic risk factors remains unknown,” says coauthor Hannah Buettner.

The investigators acknowledge that data on marijuana use were self-reported and may be subject to underestimation or denial of illicit drug use. However, they point out, underestimation of drug use would likely yield results biased toward observing no association.

Editor-in-Chief Joseph S. Alpert, MD, Professor of Medicine at the University of Arizona College of Medicine, Tucson, comments, “These are indeed remarkable observations that are supported, as the authors note, by basic science experiments that came to similar conclusions.

“We desperately need a great deal more basic and clinical research into the short- and long-term effects of marijuana in a variety of clinical settings such as cancer, diabetes, and frailty of the elderly,” continues Alpert.” I would like to call on the NIH and the DEA to collaborate in developing policies to implement solid scientific investigations that would lead to information assisting physicians in the proper use and prescription of THC in its synthetic or herbal form.””

 

Cannabis smokers ‘are less likely to develop diabetes’

“Smoking cannabis may prevent the development of diabetes, one of the most rapidly rising chronic disorders in the world.

 …it could lead to the development of treatments based on the active ingredient of cannabis, tetrahydrocannabinol (THC), without its intoxicating effects.

Researchers have found that regular users of the drug had lower levels of the hormone insulin after fasting – a signal that they are protected against diabetes. They also had reduced insulin resistance.”

Read more: http://www.independent.ie/world-news/cannabis-smokers-are-less-likely-to-develop-diabetes-29267576.html

Smoking cannabis ‘could help prevent diabetes’

“Smoking cannabis may help prevent diabetes, a new study has suggested.

Researchers found that regular users of the Class B drug had significantly lower levels of insulin after fasting – a sign of increased protected against diabetes. They also had reduced insulin resistance.

The results, reported in the American Journal of Medicine, showed current users had 16 per cent lower fasting insulin levels than participants who reported never having used marijuana.

The findings raise the possibility treatments for diabetes could be developed based on the active ingredient of cannabis, commonly known as THC.

Large waist measurements are also linked to diabetes risk and the study revealed significant associations between marijuana use and smaller waists.

Lead researcher Murray A. Mittleman, of the Cardiovascular Epidemiology Research Unit at the Beth Israel Deaconess Medical Center, Boston, said it was the first study ‘to investigate the relationship between marijuana use and fasting insulin, glucose, and insulin resistance’, The Albany Tribune reported.

But Joseph Alpert, professor of medicine at the University of Arizona College of Medicine, Tucson, and editor in chief of the American Journal of Medicine, said: ‘We desperately need a great deal more basic and clinical research into the short and long term effects of marijuana in a variety of clinical settings such as cancer diabetes and frailty of the elderly.’

Researchers studied data from 4,657 patients who completed a drug use questionnaire.

The use of so-called ‘medical marijuana’ is growing in the US where several states allow it.”

http://metro.co.uk/2013/05/15/cannabis-could-combat-diabetes-study-shows-3759797/

Cannabis linked to prevention of diabetes

“Regular users of the drug found to have lower levels of insulin after fasting, research shows. Smoking cannabis may prevent the development of diabetes, one of the most rapidly rising chronic disorders in the world.

If the link is proved, it could lead to the development of treatments based on the active ingredient of cannabis, tetrahydrocannabinol (THC), without its intoxicating effects.”

Read more: http://www.independent.co.uk/life-style/health-and-families/health-news/cannabis-linked-to-prevention-of-diabetes-8616314.html

Cannabis for Ulcerative Colitis and Crohn’s Disease treatment

“Chemicals found in cannabis could prove an effective treatment for the inflammatory bowel diseases Ulcerative Colitis and Crohn’s Disease, say scientists.

Laboratory tests have shown that two compounds found in the cannabis plant – the cannabinoids THC and cannabidiol – interact with the body’s system that controls gut function.

Crohn’s Disease and Ulcerative Colitis, which affect about one in every 250 people in Northern Europe, are caused by both genetic and environmental factors. The researchers believe that a genetic susceptibility coupled with other triggers, such as diet, stress or bacterial imbalance, leads to a defective immune response.

Dr Karen Wright, Peel Trust Lecturer in Biomedicine at Lancaster University, will be presenting her soon-to-be published work at The British Pharmacological Society’s Winter Meeting in London today (Thursday).

She said: “The lining of the intestines provides a barrier against the contents of the gut but in people with Crohn’s Disease this barrier leaks and bacteria can escape into the intestinal tissue leading to an inappropriate immune response.

“If we could find a way to restore barrier integrity in patients we may be able to curb the inflammatory immune response that causes these chronic conditions.”

Dr Wright, working with colleagues at the School of Graduate Entry Medicine and Health in Derby, has shown that cells that react to cannabinoid compounds play an important role in normal gut function as well as the immune system’s inflammatory response.

“The body produces its own cannabinoid molecules, called endocannabinoids, which we have shown increase the permeability of the epithelium during inflammation, implying that overproduction may be detrimental,” said Dr Wright.

“However, we were able to reverse this process using plant-derived cannabinoids, which appeared to allow the epithelial cells to form tighter bonds with each other and restore the membrane barrier.”

The research was carried out using cell cultures in a dish but, interestingly, when the team attempted to mimic the conditions of the gut by reducing the amount of oxygen in the cells’ environment, much lower concentrations of cannabinoid were needed to produce the same effect.

Dr Wright added: “What is also encouraging is that while THC has psychoactive properties and is responsible for the ‘high’ people experience when using cannabis, cannabidiol, which has also proved effective in restoring membrane integrity, does not possess such properties.”

The British Pharmacological Society (BPS) – the primary UK learned society concerned with research into drugs and the way they work – is hosting its annual Winter Meeting in London, attracting experts from across the world.

The three-day conference, running from 15 to 17 December 2009, will hear presentations on the latest pharmacological developments to tackle a range of conditions and diseases.”

http://www.news-medical.net/news/20091217/Cannabis-for-Ulcerative-Colitis-and-Crohns-Disease-treatment.aspx

Cannabis Induces a Clinical Response in Patients with Crohn’s Disease: a Prospective Placebo-Controlled Study.

“The marijuana plant Cannabis sativa has been reported to produce beneficial effects for patients with inflammatory bowel diseases, but these have not been investigated in controlled trials. We performed a prospective trial to determine whether cannabis can induce remission in patients with Crohn’s disease…

Complete remission was achieved by 5/11 subjects in the cannabis group (45%)… Three patients in the cannabis group were weaned from steroid dependency. Subjects receiving cannabis reported improved appetite and sleep, with no significant side effects.

CONCLUSION:

Although the primary endpoint of the study (induction of remission) was not achieved, a short course (8 week) of THC-rich cannabis produced significant clinical, steroid-free benefits to 11 patients with active CD, compared to placebo, without side effects.

Further studies, with larger patient groups and a non-smoking mode of intake, are warranted. ClinicalTrials.gov NCT01040910.”

http://www.ncbi.nlm.nih.gov/pubmed/23648372

The Cannabinoid 1 Receptor (CNR1) 1359 G/A Polymorphism Modulates Susceptibility to Ulcerative Colitis and the Phenotype in Crohn’s Disease

“Anecdotal reports suggest that marijuana- or tetrahydrocannabinol-containing products may be effective in alleviating symptoms in patients with ulcerative colitis (UC) and Crohn’s disease (CD). This is supported by recent studies of our group and others suggesting that pharmacological activation of the cannabinoid 1 (CB1) receptor with selective receptor agonists decreases the inflammatory response in various murine models of colonic inflammation…

Recent evidence suggests a crucial role of the endocannabinoid system, including the cannabinoid 1 receptor (CNR1), in intestinal inflammation. We therefore investigated the influence of the CNR1 1359 G/A (p.Thr453Thr; rs1049353) single nucleotide polymorphism (SNP) on disease susceptibility and phenotype in patients with ulcerative colitis (UC) and Crohn’s disease (CD)…

Conclusion

The CNR1 p.Thr453Thr polymorphism appears to modulate UC susceptibility and the CD phenotype. The endocannabinoid system may influence the manifestation of inflammatory bowel diseases, suggesting endocannabinoids as potential target for future therapies.

…our findings provide further evidence that endocannabinoids modulate intestinal inflammation, suggesting that this system could act as a target for future therapeutic interventions.”

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2829088/